Alzinova Management

Management criteria checks 1/4

Alzinova's CEO is Kristina Torfgard, appointed in Dec 2019, has a tenure of 4.42 years. directly owns 0.058% of the company’s shares, worth SEK32.81K. The average tenure of the management team and the board of directors is 1.3 years and 4.9 years respectively.

Key information

Kristina Torfgard

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	4.4yrs
CEO ownership	0.06%
Management average tenure	1.3yrs
Board average tenure	4.9yrs

Recent management updates

Recent updates

CEO

Kristina Torfgard

4.4yrs

Tenure

Dr. Kristina Torfgard Ph.D. serves as Chief Executive Officer at Alzinova AB since December 2019. She serves as Vice President & Global Project Head at Albireo AB. Dr. Torfgard served as Vice President of...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Kristina Torfgard	Chief Executive Officer	4.4yrs	no data	0.058% SEK 32.8k
Erik Kullgren	Interim Chief Financial Officer	less than a year	no data	no data
Anders Sandberg	Chief Scientific Officer	9.3yrs	no data	0.38% SEK 211.6k
Kirsten Harting	Chief Medical Officer	less than a year	no data	no data
Sebastian Hansson	Business Development Director	1.3yrs	no data	0.016% SEK 8.8k

1.3yrs

Average Tenure

Experienced Management: ALZ's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Anders Sandberg	Chief Scientific Officer	13.3yrs	no data	0.38% SEK 211.6k
Anders Waas	Director	5.4yrs	no data	no data
Anders Blom	Director	3yrs	no data	6.6% SEK 3.7m
Julian Aleksov	Chairman of the Board	less than a year	no data	no data
Per-Goran Gillberg	Independent Director	4.3yrs	no data	0.030% SEK 17.0k
Carol Routledge	Director	5.4yrs	no data	no data
Clas Malmestrom	Director	9.3yrs	no data	0.022% SEK 12.6k
Lena Wikingsson	Independent Director	4.3yrs	no data	no data
Jesper Dahlberg	Deputy Board Member	no data	no data	no data

4.9yrs

Average Tenure

58yo

Average Age

Experienced Board: ALZ's board of directors are considered experienced (4.9 years average tenure).

Alzinova Management

Management criteria checks 1/4

Key information

Recent management updates

Kristina Torfgård Leaves the CEO Position At Alzinova Ab, Effective July 31, 2024

Alzinova AB (publ) Announces CFO Changes

Alzinova AB (publ), Annual General Meeting, May 29, 2024

Alzinova AB (Publ) Announces Retiremet of Håkan Skogström as CFO

Alzinova AB (Publ) Appoints Kirsten Harting as New Chief Medical Officer, Effective from August 14, 2023

Alzinova AB (Publ) Elects Julian Aleksov as Board Member and Chairman of the Board of Directors

Recent updates

Alzinova AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 34.352689 million.

Alzinova AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 34.352689 million.

Price target increased by 20% to kr12.00

Kristina Torfgård Leaves the CEO Position At Alzinova Ab, Effective July 31, 2024

Alzinova AB (Publ) Announces All Patients in the Extension Part of the Phase 1B Study Have Received Their Last Dose of ALZ-101

Alzinova AB (publ) Announces CFO Changes

Full year 2023 earnings released: kr0.37 loss per share (vs kr0.54 loss in FY 2022)

New major risk - Revenue and earnings growth

Alzinova AB (Publ) Receives Regulatory Approval to Evaluate A Higher Dose of the Vaccine Candidate Alz-101 in the Ongoing Phase 1B Study

Alzinova AB (publ) to Report Fiscal Year 2024 Results on Feb 27, 2025

New major risk - Market cap size

Alzinova AB Announces Primary Analysis Confirms Positive Phase 1B Results with ALZ-101 against Alzheimer's

Alzinova AB (publ), Annual General Meeting, May 29, 2024

Alzinova AB (Publ) Announces Retiremet of Håkan Skogström as CFO

Alzinova AB (publ) Announces Positive Phase 1b Results with the Vaccine Candidate ALZ-101 Against Alzheimer's Disease

Third quarter 2023 earnings released

New minor risk - Share price stability

New major risk - Market cap size

Alzinova AB (publ) Receives Positive Response from the European Medicines Agency EMA

Second quarter 2023 earnings released

Alzinova AB (Publ) Appoints Kirsten Harting as New Chief Medical Officer, Effective from August 14, 2023

Alzinova AB (publ) Submits Request for Pre-IND Meeting with FDA and Applies for EMA Scientific Advice

Alzinova AB (Publ) Elects Julian Aleksov as Board Member and Chairman of the Board of Directors

First quarter 2023 earnings released

Director exercised options to buy kr8.7m worth of stock.

Chief Executive Officer exercised options to buy kr66k worth of stock.

Full year 2022 earnings released: kr0.40 loss per share (vs kr0.48 loss in FY 2021)

Alzinova AB (publ) Appoints Sebastian Hansson as the New Business Development Director

Alzinova AB (publ) Announces New Positive Safety Review and Interim Data from Ongoing Phase 1B Study with Vaccine Candidate ALZ-101

Alzinova AB (publ) Presents Data for its Preclinical Antibody Candidate ALZ-201 at Annual Alzheimer's Conference CTAD, Clinical Trials in Alzheimer's Disease

Alzinova AB (publ) to Report Fiscal Year 2023 Results on Feb 28, 2024

Less than half of directors are independent

Third quarter 2022 earnings released

Alzinova AB (publ) to Report Fiscal Year 2022 Results on Feb 23, 2023

Alzinova AB (Publ) Announces New Positive Safety Review of Its Phase 1B Study in Alzheimer's Disease

Second quarter 2022 earnings released

Alzinova AB (publ) Recruits Half of Patients for the Ongoing Phase 1B Study of the Vaccine Candidate ALZ-101

Alzinova AB (publ) Establishes Scaled-Up Manufacturing Process for ALZ-101 Ahead of Phase 2

Alzinova AB (publ) Initiates Development of a Stable Cell Line to Prepare the Monoclonal Antibody ALZ-201 for Alzheimer's Clinical Trials

Alzinova AB (publ) Initiates Development of a Stable Cell Line to Prepare the Monoclonal Antibody ALZ-201 for Alzheimer's Clinical Trials

Less than half of directors are independent

Full year 2021 earnings released: kr0.48 loss per share (vs kr0.41 loss in FY 2020)

Alzinova Improves Manufacturing Process of ALZ-101 to Meet Phase 2 Requirements

Full year 2021 earnings: EPS misses analyst expectations

Alzinova AB to Report Fiscal Year 2021 Results on Apr 14, 2022

Alzinova AB (publ) Completes Humanisation Work and Selects Lead Candidate for Monoclonal Antibody ALZ-201

Third quarter 2021 earnings released

Second quarter 2021 earnings released

First quarter 2021 earnings released

Full year 2020 earnings released: kr0.85 loss per share (vs kr0.81 loss in FY 2019)

Alzinova AB to Report Q3, 2021 Results on Oct 28, 2021

Alzinov AB Announces Drug Substance for the ALZ-101 Vaccine is Now Produced

New 90-day low: kr6.94

New 90-day low: kr7.30

Alzinova AB Announces the Study Design for the First Clinical Study with the Oligomer-Specific Therapeutic Vaccine ALZ-101 at a Scientific Congress

Third quarter earnings released

Alzinova AB (publ) Receives Positive Feedback from the Finnish Medicines Agency Fimea in View of the Upcoming Clinical Trial Application for the Alz-101 Alzheimer's Disease Vaccine

New 90-day low: kr8.68

New 90-day low - kr9.66

Earnings released

CEO

Tenure

Leadership Team

Average Tenure

Board Members

Average Tenure

Average Age